Roger Waters: Antisemitism is odious, and I condemn it
(London, UK): Statement by Mr George Roger Waters dated 16.03.2023:
“My lawyers are taking steps to ensure that my concerts in Munich and Frankfurt in May 2023 take place as contracted. Human rights and freedom of speech for all peoples under German law must prevail, which is why I’m taking this stance to ensure the will of the few will not prevent me from performing in Frankfurt and Munich.
I am taking the unprecedented step of appealing to the law to protect me from the unconstitutional actions of two authorities which seem to rely upon the fundamentally false accusation that has been made against me; namely that I am antisemitic.
I want to state for the record and once and for all that I am not and never have been antisemitic and nothing that anyone can say or publish will alter that. My well-publicized views relate entirely to the policies and actions of the Israeli government and not with the peoples of Israel. Antisemitism is odious and racist, and I condemn it, along with all forms of racism unreservedly.
I am not going to and do not need to keep making my position clear on this issue. I am confident that truth and the law will prevail and that these authorities will not succeed in denying any of my basic human rights.”
Publisher:
Mark Fenwick Management – London
on behalf of Mr George Roger Waters
Kontakter
Press Contact:
HÖCKER Rechtsanwälte PartGmbB
Rechtsanwalt Prof. Dr. Ralf Höcker
Rechtsanwalt Michael Fengler
Friesenplatz 1
50672 Köln
Germany
E-Mail: contact@hoecker.eu
Tel: +49(0)221-93319-10
Fax: +49(0)221-93319-110
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.
Bertelsmann Stiftung: Growth and innovation as cornerstones of a strong de-mocracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Press release
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds28.4.2025 08:33:05 CEST | Press release
Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
EOPA Best Business Product of the Year 2025 - DYMO LetraTag 200B (Source:OPI)25.4.2025 08:00:04 CEST | Press release
DYMO® LETRATAG 200B WINS PRESTIGIOUS “BUSINESS PRODUCT OF THE YEAR” AWARD - REINFORCING RISE OF SMART ORGANIZATION
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom